Understanding Duchenne muscular dystrophy-associated brain pathology
Open accessThe DOI matches its Crossref record; 203 of the 204 references it cites were found in a registry or an index; none of the 273 sources its claims cite is checked for support yet.
Abstract
The most common neuromuscular disorder, Duchenne muscular dystrophy (DMD), is caused by mutations in the DMD gene, resulting in a lack of dystrophin. In addition to severe and progressive muscle wasting, a subset of individuals with DMD experience, to largely varying extents, behavioural and cognitive deficits, including a lower IQ, and neurological comorbidities, such as autism spectrum disorder, obsessive compulsive disorder and attention deficit hyperactivity disorder. Neuroimaging studies in individuals with DMD have identified widespread pathology, including structural, physiological and connective alterations. DMD mouse models exhibit a number of DMD-associated behavioural traits, including anxiety, social deficits and learning disabilities, and have been used to investigate DMD brain pathology. Although there are currently no therapies to treat DMD brain pathology, genetic approaches are being developed to restore dystrophin expression. In particular, the exon skipping approach shows promise in ameliorating certain DMD-associated behavioural deficits in preclinical settings. However, the therapeutic potential of postnatal restoration of dystrophin isoforms involved in neurodevelopment is unknown. Furthermore, challenges such as low dystrophin restoration efficacy and translatability from DMD mouse models to the clinic remain to be addressed.
Overview
CoChat Summary
TL;DR
This review synthesizes human and preclinical evidence that Duchenne muscular dystrophy (DMD) involves brain pathology beyond muscle, with cognitive/behavioural deficits in ∼30% of individuals and widespread neuroimaging, neurochemical and synaptic alterations. It highlights DMD mouse models and preclinical exon-skipping approaches that partially restore brain dystrophin and improve some behavioural phenotypes, while noting major gaps in efficacy, translatability and postnatal restoration of neurodevelopmental isoforms.
Key findings
- About 30% of individuals with DMD have cognitive/behavioural deficits; average IQ is reported as mean=84.76 versus general population mean=100, with comorbidities including ASD ∼6%, OCD ∼7%, ADHD ∼16% and epileptic seizures 5%.
- Neuroimaging in DMD shows decreased total brain volume and global grey matter reductions, white matter microstructural deficits (increased diffusivity, lower fractional anisotropy), default mode network hyperconnectivity, reduced cerebral blood flow and altered motor cortex function; some changes are more pronounced in individuals lacking both Dp427 and Dp140, but findings are inconsistent.
- DMD mouse models show behavioural phenotypes including severe restraint-induced freezing in mdx/bl10 lasting at least 1 h, anxiety that worsens with loss of Dp140 and all isoforms, learning/memory deficits, social deficits and altered ultrasonic vocalizations; DMD-null mice also show restless behaviour and altered day/night rhythms.
- Preclinical exon skipping in mdx/bl10 and mdx52 mice restores dystrophin at low levels (e.g. 5–25% in several studies; exon 53 skipping restored 1% Dp427 and 5% Dp140 in one study) and can improve fear, anxiety or ASD-like behaviour, but postnatal restoration of Dp140 and Dp427p remains of unknown therapeutic value.
Methods
- Design: narrative review of DMD-associated brain pathology, animal models and therapy development, with a focus on exon skipping for brain dystrophin restoration.
- Data/sample: published human post-mortem, neuroimaging, neuropsychological and clinical literature, plus preclinical studies in mouse, rat, dog and pig DMD models; no primary data were generated.
- Main analysis: qualitative synthesis of cited studies, including summary tables of behavioural deficits in DMD mouse models (Table 1) and exon-skipping approaches in the DMD mouse brain (Table 2).
Limitations
- Stated in the paper: clinical neuroimaging studies are limited by small sample sizes (often ∼15 participants), underrepresentation of distal mutations affecting multiple/all dystrophin isoforms, variability in corticosteroid regimens/dosages/duration, and largely correlative findings that cannot establish causality.
- Stated in the paper: DMD mouse models are usually steroid-naïve, differ from humans in brain complexity and dystrophin isoform spatiotemporal expression, and face challenges of low dystrophin restoration efficacy and limited translatability to the clinic.
- Evident from the text: as a narrative review, it does not systematically appraise or meta-analyze the literature, and it repeatedly notes conflicting or inconclusive findings across studies, including inconsistent anxiety, depressive-like behaviour, memory and neuroimaging results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
0 Valid · 4 Not valid · 159 Not checked · 78 Own results and interpretations
None of the sources cited for this claim have been checked yet.
In the paper
“attention deficit hyperactivity disorder (ADHD; ∼16%) (Hendriksen and Vles, 2008; Ricotti et al., 2016; Darmahkasih et al., 2020; Pascual-Morena et al., 2023)”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Behavioural deficits and brain pathology in DMD
What the sources say
- Not checked yetcites Hendriksen and Vles, 2008 matched to “Neuropsychiatric Disorders in Males With Duchenne Muscular Dystrophy: Frequency Rate of Attention-Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder, and Obsessive—Compulsive Disorder” (2008) source
- Not checked yetcites Ricotti et al., 2016 matched to “Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations” (2016) source
- Not checked yetcites Darmahkasih et al., 2020 matched to “Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy” (2020) source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Notably, mutations occurring downstream of exon 63 in the DMD gene have also been associated with more rapid progression of motor impairment in individuals with DMD, indicating that the specific mutation location influences the severity and timing of functional decline (Chesshyre et al., 2022; Muntoni et al., 2023).”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Behavioural deficits and brain pathology in DMD
What the sources say
- Not checked yetcites Chesshyre et al., 2022 matched to “Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy” (2022) source
- Not checked yetcites Muntoni et al., 2023 matched to “DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials” (2023) source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The average IQ of the DMD population (mean=84.76) is one standard deviation below that of the general population (mean=100) (Hinton et al., 2000; Cotton et al., 2001; Cyrulnik et al., 2008; Connolly et al., 2013; Weerkamp et al., 2022).”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Behavioural deficits and brain pathology in DMD
What the sources say
- Not checked yetcites Hinton et al., 2000 matched to “Poor verbal working memory across intellectual level in boys with Duchenne dystrophy” (2000) source
- Not checked yetcites Cotton et al., 2001 matched to “Intelligence and Duchenne muscular dystrophy: Full-Scale, Verbal, and Performance intelligence quotients” (2001) source
- Not checked yetcites Cyrulnik et al., 2008 matched to “Cognitive and adaptive deficits in young children with Duchenne muscular dystrophy (DMD)” (2008) source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“However, there remains notable variability in both motor and central nervous system (CNS) outcomes, even among individuals with mutations affecting the 3′ end of the gene, implying that mutation location alone does not fully explain the phenotypic differences (Fang et al., 2025).”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Behavioural deficits and brain pathology in DMD
What the sources say
- Not checked yetcites Fang et al., 2025 matched to “Association of DMD Gene Variant Classes With Motor Outcomes in a Drug Registration Clinical Trial Setting” (2025) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Approximately 30% of them have a higher risk of cognitive impairment, learning disabilities and delayed developmental milestones (Ricotti et al., 2016; Colombo et al., 2017; Darmahkasih et al., 2020).”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Behavioural deficits and brain pathology in DMD
What the sources say
- Not checked yetcites Ricotti et al., 2016 matched to “Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations” (2016) source
- Not checked yetcites Colombo et al., 2017 matched to “Assessing mental health in boys with Duchenne muscular dystrophy: Emotional, behavioural and neurodevelopmental profile in an Italian clinical sample” (2017) source
- Not checked yetcites Darmahkasih et al., 2020 matched to “Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy” (2020) source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
101 more claims
Create a free account to see all 241 claims and to verify the 249 references still open.
- Probably not a substantial claim. 32
- It may state two separate claims as one. 107
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Therapy development for the DMD brain > Exon skipping to treat the DMD brain
“| Mdx/bl10 | Tc-DNA | 23 | 200 mg/kg weekly | IV | 12 weeks | 2-4% | Low (not quantified) | Yes (fear response) | Goyenvalle et al., 2015 |”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Therapy development for the DMD brain > Exon skipping to treat the DMD brain
“Because tc-DNA AONs can cross the blood–brain barrier, this systemic treatment resulted in exon 23 skipping and in the restoration of ∼5% of full-length dystrophin compared to WT dystrophin levels as assessed by western blotting, which led to improvements in the restraint-induced fear response in this model.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Therapy development for the DMD brain > Exon skipping to treat the DMD brain
“This, in turn, resulted in a ∼25% increase in dystrophin levels (compared to WT levels) and improvements in the fear response.”
§ Understanding Duchenne muscular dystrophy-associated brain pathology > Therapy development for the DMD brain > Exon skipping to treat the DMD brain
“Dystrophin levels changed over time during this study and were highest 6-7 weeks after treatment (up to 15% of WT levels), and gradually decreased towards week 10.”
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Duan, D., Goemans, N., Takeda, S., Mercuri, E., & Aartsma-Rus, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00248-3 · Cited by 1,312
The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., & Barnard, P. J. (1989) · Science · doi:10.1126/science.2662404 · Cited by 1,276
The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
Bladen, C. L., Salgado, D., Monges, S., Foncuberta, M. E., Kekou, K., Kosma, K., Dawkins, H., Lamont, L., Roy, A. J., Chamova, T., et al. (2015) · Human Mutation · doi:10.1002/humu.22758 · Cited by 729
Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., Mercuri, E., & for the Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) · Annals of Neurology · doi:10.1002/ana.24555 · Cited by 518
Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping
Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.-C., Garcia, L., & Danos, O. (2004) · Science · doi:10.1126/science.1104297 · Cited by 506
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Frank, D. E., Schnell, F. J., Akana, C., El-Husayni, S. H., Desjardins, C. A., Morgan, J., Charleston, J. S., Sardone, V., Domingos, J., Dickson, G., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009233 · Cited by 332
Ricotti, V., Mandy, W. P. L., Scoto, M., Pane, M., Deconinck, N., Messina, S., Mercuri, E., Skuse, D. H., & Muntoni, F. (2016) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12922 · Cited by 332
Goyenvalle, A., Griffith, G., Babbs, A., Andaloussi, S. E., Ezzat, K., Avril, A., Dugovic, B., Chaussenot, R., Ferry, A., Voit, T., et al. (2015) · Nature Medicine · doi:10.1038/nm.3765 · Cited by 327
The Pathogenesis and Therapy of Muscular Dystrophies
Guiraud, S., Aartsma-Rus, A., Vieira, N. M., Davies, K. E., van Ommen, G.-J. B., & Kunkel, L. M. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-025003 · Cited by 302
Dp140: a novel 140 kDa CNS transcript from the dystrophin locus
Lidov, H. G. W., Selig, S., & Kunkel, L. M. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.3.329 · Cited by 281
Hendriksen, J. G. M., & Vles, J. S. H. (2008) · Journal of Child Neurology · doi:10.1177/0883073807309775 · Cited by 281
Cyclical palmitoylation regulates TLR9 signalling and systemic autoimmunity in mice
Ni, H., Wang, Y., Yao, K., Wang, L., Huang, J., Xiao, Y., Chen, H., Liu, B., Yang, C. Y., & Zhao, J. (2024) · Nature Communications · doi:10.1038/s41467-023-43650-z · Cited by 281
Shirley, M. (2021) · Drugs · doi:10.1007/s40265-021-01512-2 · Cited by 274
Górecki, D. C., Monaco, A. P., Derry, J. M. J., Walker, A. P., Barnard, E. A., & Barnard, P. J. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.7.505 · Cited by 265
Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis
Broomfield, J., Hill, M., Guglieri, M., Crowther, M. J., & Abrams, K. R. (2021) · Neurology · doi:10.1212/wnl.0000000000012910 · Cited by 264
Conservation of the Duchenne Muscular Dystrophy Gene in Mice and Humans
Hoffman, E. P., Monaco, A. P., Feener, C. C., & Kunkel, L. M. (1987) · Science · doi:10.1126/science.3659917 · Cited by 258
Corticosteroid-related central nervous system side effects
Ciriaco, M., Ventrice, P., Russo, G., Scicchitano, M., Mazzitello, G., Scicchitano, F., & Russo, E. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.120975 · Cited by 244
Cotton, S., Voudouris, N. J., & Greenwood, K. M. (2001) · Developmental Medicine and Child Neurology · doi:10.1017/s0012162201000913 · Cited by 241
Altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice)
Knuesel, I., Mastrocola, M., Zuellig, R. A., Bornhauser, B., Schaub, M. C., & Fritschy, J. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00887.x · Cited by 241
Different Dystrophin-like Complexes Are Expressed in Neurons and Glia
Blake, D. J., Hawkes, R., Benson, M. A., & Beesley, P. W. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.3.645 · Cited by 232
Doorenweerd, N., Mahfouz, A., van Putten, M., Kaliyaperumal, R., t’ Hoen, P. A. C., Hendriksen, J. G. M., Aartsma-Rus, A. M., Verschuuren, J. J. G. M., Niks, E. H., Reinders, M. J. T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12981-5 · Cited by 221
The dystrophin–glycoprotein complex in brain development and disease
Waite, A., Brown, S. C., & Blake, D. J. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.04.004 · Cited by 215
Differential expression of dystrophin isoforms in strains of mdx mice with different mutations
Im, W. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.8.1149 · Cited by 212
Haché, M., Swoboda, K. J., Sethna, N., Farrow-Gillespie, A., Khandji, A., Xia, S., & Bishop, K. M. (2016) · Journal of Child Neurology · doi:10.1177/0883073815627882 · Cited by 208
Taylor, P. J., Betts, G. A., Maroulis, S., Gilissen, C., Pedersen, R. L., Mowat, D. R., Johnston, H. M., & Buckley, M. F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008803 · Cited by 208
Aquaporin‐4 deficiency in skeletal muscle and brain of dystrophic mdx mice
FRIGERI, A., NICCHIA, G. P., NICO, B., QUONDAMATTEO, F., HERKEN, R., RONCALI, L., & SVELTO, M. (2001) · The FASEB Journal · doi:10.1096/fj.00-0260com · Cited by 198
Cognitive impairment in Duchenne muscular dystrophy
Bresolin, N., Castelli, E., Comi, G. P., Felisari, G., Bardoni, A., Perani, D., Grassi, F., Turconi, A., Mazzucchelli, F., Gallotti, D., et al. (1994) · Neuromuscular Disorders · doi:10.1016/0960-8966(94)90072-8 · Cited by 198
Desguerre, I., Christov, C., Mayer, M., Zeller, R., Becane, H.-M., Bastuji-Garin, S., Leturcq, F., Chiron, C., Chelly, J., & Gherardi, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004347 · Cited by 195
The role of corticosteroids in muscular dystrophy: A critical appraisal
Angelini, C. (2007) · Muscle & Nerve · doi:10.1002/mus.20812 · Cited by 191
Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: A review
Snow, W. M., Anderson, J. E., & Jakobson, L. S. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.016 · Cited by 189
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
Mendell, J. R., Muntoni, F., McDonald, C. M., Mercuri, E. M., Ciafaloni, E., Komaki, H., Leon-Astudillo, C., Nascimento, A., Proud, C., Schara-Schmidt, U., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03304-z · Cited by 183
Clinical and genetic characterization of manifesting carriers of DMD mutations
Soltanzadeh, P., Friez, M. J., Dunn, D. M., von Niederhausern, A. C., Gurvich, O. L., Swoboda, K. J., Sampson, J. B., Pestronk, A., Connolly, A. M., Florence, J. M., et al. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.05.010 · Cited by 181
Pane, M., Lombardo, M. E., Alfieri, P., D'Amico, A., Bianco, F., Vasco, G., Piccini, G., Mallardi, M., Romeo, D. M., Ricotti, V., et al. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.03.020 · Cited by 178
Severe alterations of endothelial and glial cells in the blood‐brain barrier of dystrophic mdx mice
Nico, B., Frigeri, A., Nicchia, G. P., Corsi, P., Ribatti, D., Quondamatteo, F., Herken, R., Girolamo, F., Marzullo, A., Svelto, M., et al. (2003) · Glia · doi:10.1002/glia.10216 · Cited by 172
Vaillend, C., Billard, J.-M., & Laroche, S. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.05.004 · Cited by 169
Poor verbal working memory across intellectual level in boys with Duchenne dystrophy
Hinton, V. J., De Vivo, D. C., Nereo, N. E., Goldstein, E., & Stern, Y. (2000) · Neurology · doi:10.1212/wnl.54.11.2127 · Cited by 169
Feeling Strained? Influence of Genetic Background on Depression-Related Behavior in Mice: A Review
Jacobson, L. H., & Cryan, J. F. (2007) · Behavior Genetics · doi:10.1007/s10519-006-9106-3 · Cited by 167
Wolfer, D. P., & Lipp, H.-P. (2000) · Experimental Physiology · doi:10.1017/s0958067000020959 · Cited by 167
Araki, E., Nakamura, K., Nakao, K., Kameya, S., Kobayashi, O., Nonaka, I., Kobayashi, T., & Katsuki, M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7328 · Cited by 161
Cholinergic circuits in cognitive flexibility
Prado, V. F., Janickova, H., Al-Onaizi, M. A., & Prado, M. A. M. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2016.09.013 · Cited by 150
Hughes, M. C., Ramos, S. V., Turnbull, P. C., Rebalka, I. A., Cao, A. W., Monaco, C. M. F., Varah, N. E., Edgett, B. A., Huber, J. S., Tadi, P., et al. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12405 · Cited by 149
Sekiguchi, M., Zushida, K., Yoshida, M., Maekawa, M., Kamichi, S., Yoshida, M., Sahara, Y., Yuasa, S., Takeda, S., & Wada, K. (2009) · Brain · doi:10.1093/brain/awn253 · Cited by 147
Mental deficiency associated with muscular dystrophy: a neuropathological study
ROSMAN, N. P., & KAKULAS, B. A. (1966) · Brain · doi:10.1093/brain/89.4.769 · Cited by 141
McLin, J. P., & Steward, O. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05111.x · Cited by 139
The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy
Danko, I., Chapman, V., & Wolff, J. A. (1992) · Pediatric Research · doi:10.1203/00006450-199207000-00025 · Cited by 136
Cellular, Synaptic and Network Effects of Acetylcholine in the Neocortex
Colangelo, C., Shichkova, P., Keller, D., Markram, H., & Ramaswamy, S. (2019) · Frontiers in Neural Circuits · doi:10.3389/fncir.2019.00024 · Cited by 133
Connolly, A. M., Florence, J. M., Cradock, M. M., Malkus, E. C., Schierbecker, J. R., Siener, C. A., Wulf, C., Anand, P., Golumbek, P. T., Zaidman, C. M., et al. (2013) · Neuromuscular Disorders · doi:10.1016/j.nmd.2013.04.005 · Cited by 132
Reduced cerebral gray matter and altered white matter in boys with Duchenne muscular dystrophy
Doorenweerd, N., Straathof, C. S., Dumas, E. M., Spitali, P., Ginjaar, I. B., Wokke, B. H., Schrans, D. G., van den Bergen, J. C., van Zwet, E. W., Webb, A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24222 · Cited by 127
Daoud, F., Candelario-Martínez, A., Billard, J.-M., Avital, A., Khelfaoui, M., Rozenvald, Y., Guegan, M., Mornet, D., Jaillard, D., Nudel, U., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006574 · Cited by 123
Perronnet, C., & Vaillend, C. (2010) · BioMed Research International · doi:10.1155/2010/849426 · Cited by 120
Vaillend, C., Rendon, A., Misslin, R., & Ungerer, A. (1995) · Behavior Genetics · doi:10.1007/bf02327580 · Cited by 112
HINTON, V. J., DE VIVO, D. C., NEREO, N. E., GOLDSTEIN, E., & STERN, Y. (2001) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617701711058 · Cited by 112
Skupio, U., Tertil, M., Sikora, M., Gołda, S., Wawrzczak‐Bargieła, A., & Przewłocki, R. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.11.035 · Cited by 103
A sarcoglycan-dystroglycan complex anchors Dp116 and utrophin in the peripheral nervous system
Imamura, M., Araishi, K., Noguchi, S., & Ozawa, E. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.20.3091 · Cited by 101
Investigation of Poor Academic Achievement in Children with Duchenne Muscular Dystrophy
Hinton, V. J., Vivo, D. C. D., Fee, R. J., Goldstein, E., & Stern, Y. (2004) · Learning Disabilities Research and Practice · doi:10.1111/j.1540-5826.2004.00098.x · Cited by 99
Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy
Darmahkasih, A. J., Rybalsky, I., Tian, C., Shellenbarger, K. C., Horn, P. S., Lambert, J. T., & Wong, B. L. (2020) · Muscle & Nerve · doi:10.1002/mus.26803 · Cited by 99
Viltolarsen for the treatment of Duchenne muscular dystrophy
Roshmi, R. R., & Yokota, T. (2019) · Drugs of today · doi:10.1358/dot.2019.55.10.3045038 · Cited by 99
Viggiano, E., Ergoli, M., Picillo, E., & Politano, L. (2016) · Human Genetics · doi:10.1007/s00439-016-1666-6 · Cited by 96
Passive avoidance behaviour deficit in the mdx mouse
Muntoni, F., Mateddu, A., & Serra, G. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90059-2 · Cited by 96
Bello, L., & Pegoraro, E. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050649 · Cited by 95
Effects of acute prednisone administration on memory, attention and emotion in healthy human adults
Schmidt, L. A., Fox, N. A., Goldberg, M. C., Smith, C. C., & Schulkin, J. (1999) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(99)00007-4 · Cited by 88
Social behavior problems in boys with Duchenne muscular dystrophy
HINTON, V. J., NEREO, N. E., FEE, R. J., & CYRULNIK, S. E. (2006) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200612000-00003 · Cited by 88
Kueh, S., Head, S., & Morley, J. W. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04816.x · Cited by 87
Premature termination codons in the DMD gene cause reduced local mRNA synthesis
García‐Rodríguez, R., Hiller, M., Jiménez-Gracia, L., van der Pal, Z., Balog, J., Adamzek, K., Aartsma-Rus, A. M., & Spitali, P. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910456117 · Cited by 86
Are Males With Duchenne Muscular Dystrophy at Risk for Reading Disabilities?
Hendriksen, J. G. M., & Vles, J. S. H. (2006) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.08.029 · Cited by 85
Dieterich, A., Srivastava, P., Sharif, A., Stech, K., Floeder, J. R., Yohn, S. E., & Samuels, B. A. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0674-4 · Cited by 84
Split intein-mediated protein trans-splicing to express large dystrophins
Tasfaout, H., Halbert, C. L., McMillen, T. S., Allen, J. M., Reyes, T. R., Flint, G. V., Grimm, D., Hauschka, S. D., Regnier, M., & Chamberlain, J. S. (2024) · Nature · doi:10.1038/s41586-024-07710-8 · Cited by 83
Radley‐Crabb, H. G., Marini, J. C., Sosa, H. A., Castillo, L. I., Grounds, M. D., & Fiorotto, M. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089277 · Cited by 83
Relizani, K., Griffith, G., Echevarría, L., Zarrouki, F., Facchinetti, P., Vaillend, C., Leumann, C., Garcia, L., & Goyenvalle, A. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.06.013 · Cited by 83
Altered regional brain glucose metabolism in Duchenne muscular dystrophy: A PET study
Lee, J. S., Pfund, Z., Juhász, C., Behen, M. E., Muzik, O., Chugani, D. C., Nigro, M. A., & Chugani, H. T. (2002) · Muscle & Nerve · doi:10.1002/mus.10238 · Cited by 81
Cognitive and adaptive deficits in young children with Duchenne muscular dystrophy (DMD)
CYRULNIK, S. E., FEE, R. J., BATCHELDER, A., KIEFEL, J., GOLDSTEIN, E., & HINTON, V. J. (2008) · Journal of the International Neuropsychological Society · doi:10.1017/s135561770808106x · Cited by 80
Brain morphology in Duchenne muscular dystrophy: a Golgi study
Jagadha, V., & Becker, L. E. (1988) · Pediatric Neurology · doi:10.1016/0887-8994(88)90047-1 · Cited by 80
The central nervous system in duchenne muscular dystrophy
DUBOWITZ, V., & CROME, L. (1969) · Brain · doi:10.1093/brain/92.4.805 · Cited by 80
Central nervous system involvement in progressive muscular dystrophy
Yoshioka, M., Okuno, T., Honda, Y., & Nakano, Y. (1980) · Archives of Disease in Childhood · doi:10.1136/adc.55.8.589 · Cited by 80
Association between loss of Dp140 and cognitive impairment in Duchenne and Becker dystrophies
Chamova, T., Guergueltcheva, V, Raycheva, M., Todorov, T., Genova, J., Bichev, S., Bojinova, V, Mitev, V, Tournev, I., & Todorova, A. (2013) · Balkan Journal of Medical Genetics · doi:10.2478/bjmg-2013-0014 · Cited by 80
Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
Alfano, L. N., Charleston, J. S., Connolly, A. M., Cripe, L., Donoghue, C., Dracker, R., Dworzak, J., Eliopoulos, H., Frank, D. E., Lewis, S., et al. (2019) · Medicine · doi:10.1097/md.0000000000015858 · Cited by 79
Colombo, P., Nobile, M., Tesei, A., Civati, F., Gandossini, S., Mani, E., Molteni, M., Bresolin, N., & D'Angelo, G. (2017) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2017.02.007 · Cited by 78
Battini, R., Chieffo, D., Bulgheroni, S., Piccini, G., Pecini, C., Lucibello, S., Lenzi, S., Moriconi, F., Pane, M., Astrea, G., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.11.018 · Cited by 75
Predictors of death in adults with duchenne muscular dystrophy-associated cardiomyopathy
Cheeran, D., Khan, S., Khera, R., Bhatt, A., Garg, S., Grodin, J. L., Morlend, R., Araj, F. G., Amin, A. A., Thibodeau, J. T., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006340 · Cited by 75
Structural changes in the early stages of Duchenne muscular dystrophy
Bradley, W. G., Hudgson, P., Larson, P. F., Papapetropoulos, T., & Jenkison, M. (1972) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.35.4.451 · Cited by 74
Duchenne muscular dystrophy: recent insights in brain related comorbidities
Vaillend, C., Aoki, Y., Mercuri, E., Hendriksen, J., Tetorou, K., Goyenvalle, A., & Muntoni, F. (2025) · Nature Communications · doi:10.1038/s41467-025-56644-w · Cited by 73
Miranda, R., Sebrie, C., Degrouard, J., Gillet, B., Jaillard, D., Laroche, S., & Vaillend, C. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn135 · Cited by 70
mdx Mice Manifest More Severe Muscle Dysfunction and Diaphragm Force Deficits than Do mdx Mice
Beastrom, N., Lu, H., Macke, A., Canan, B. D., Johnson, E. K., Penton, C. M., Kaspar, B. K., Rodino-Klapac, L. R., Zhou, L., Janssen, P. M. L., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.009 · Cited by 69
Poysky, J. (2007) · Neuromuscular Disorders · doi:10.1016/j.nmd.2007.06.465 · Cited by 69
Non-sequential and multi-step splicing of the dystrophin transcript
Gazzoli, I., Pulyakhina, I., Verwey, N. E., Ariyurek, Y., Laros, J. F. J., 't Hoen, P. A. C., & Aartsma-Rus, A. (2016) · RNA Biology · doi:10.1080/15476286.2015.1125074 · Cited by 68
Duchenne muscular dystrophy and epilepsy
Pane, M., Messina, S., Bruno, C., D’Amico, A., Villanova, M., Brancalion, B., Sivo, S., Bianco, F., Striano, P., Battaglia, D., et al. (2013) · Neuromuscular Disorders · doi:10.1016/j.nmd.2013.01.011 · Cited by 67
Kudoh, H., Ikeda, H., Kakitani, M., Ueda, A., Hayasaka, M., Tomizuka, K., & Hanaoka, K. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.191 · Cited by 67
Chesshyre, M., Ridout, D., Hashimoto, Y., Ookubo, Y., Torelli, S., Maresh, K., Ricotti, V., Abbott, L., Gupta, V. A., Main, M., et al. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12914 · Cited by 66
A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
Veltrop, M., van Vliet, L., Hulsker, M., Claassens, J., Brouwers, C., Breukel, C., van der Kaa, J., Linssen, M. M., den Dunnen, J. T., Verbeek, S., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193289 · Cited by 64
Vaillend, C., & Billard, J. (2002) · Hippocampus · doi:10.1002/hipo.10068 · Cited by 63
Neurobehavioral characteristics of children with duchenne muscular dystrophy
Donders, J., & Taneja, C. (2009) · Child Neuropsychology · doi:10.1080/09297040802665777 · Cited by 62
Intellectual Ability in the Duchenne Muscular Dystrophy and Dystrophin Gene Mutation Location
Rasic, M., Vojinović, D., Pešović, J., Mijalkovic, G., Lukic, V., Mladenovic, J., Kosać, A., Novaković, I. V., Maksimović, N., Romac, S. P., et al. (2014) · Balkan Journal of Medical Genetics · doi:10.2478/bjmg-2014-0071 · Cited by 62
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Zhou, Y., Zhang, C., Xiao, W., Herzog, R. W., & Han, R. (2024) · Nature Communications · doi:10.1038/s41467-024-50569-6 · Cited by 60
Vaillend, C., Perronnet, C., Ros, C., Gruszczynski, C., Goyenvalle, A., Laroche, S., Danos, O., Garcia, L., & Peltekian, E. (2010) · Molecular Therapy · doi:10.1038/mt.2010.134 · Cited by 59
Chaussenot, R., Edeline, J.-M., Le Bec, B., El Massioui, N., Laroche, S., & Vaillend, C. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.07.006 · Cited by 59
Vaillend, C., Billard, J.-M., Claudepierre, T., Rendon, A., Dutar, P., & Ungerer, A. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00023-2 · Cited by 59
Corticosteroids and cognition: a meta-analysis
Prado, C. E., & Crowe, S. F. (2019) · Neuropsychology Review · doi:10.1007/s11065-019-09405-8 · Cited by 58
van Roon‐Mom, W., Ferguson, C. M., & Aartsma-Rus, A. M. (2023) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0027 · Cited by 53
Decreased cerebral perfusion in Duchenne muscular dystrophy patients
Doorenweerd, N., Dumas, E. M., Ghariq, E., Schmid, S., Straathof, C. S. M., Roest, A. A. W., Wokke, B. H. A., van Zwet, E. W., WEBB, A. G., Hendriksen, J. G. M., et al. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.10.005 · Cited by 53
Rae, C., Scott, R. B., Thompson, C. H., Dixon, R. M., Dumughn, I., J. Kemp, G., Male, A., Pike, M., Styles, P., & Radda, G. K. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00190-7 · Cited by 53
Dysfunctional muscle and liver glycogen metabolism in mdx dystrophic mice
Stapleton, D. I., Lau, X., Flores, M., Trieu, J., Gehrig, S. M., Chee, A., Naim, T., Lynch, G. S., & Koopman, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091514 · Cited by 53
An open-source video tracking system for mouse locomotor activity analysis
Zhang, C., Bailin, P. L., & Han, R. (2020) · BMC Research Notes · doi:10.1186/s13104-020-4916-6 · Cited by 53
A comparison of the behavior of C57BL/6 and C57BL/10 mice
Deacon, R. M. J., Thomas, C., Rawlins, J. N. P., & Morley, B. J. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.02.009 · Cited by 52
Behavioral characterization of mdx3cv mice deficient in C-terminal dystrophins
Vaillend, C., & Ungerer, A. (1999) · Neuromuscular Disorders · doi:10.1016/s0960-8966(99)00029-2 · Cited by 52
Hashimoto, Y., Kuniishi, H., Sakai, K., Fukushima, Y., Du, X., Yamashiro, K., Hori, K., Imamura, M., Hoshino, M., Yamada, M., et al. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102288 · Cited by 51
Brain metabolism is abnormal in the mdx model of Duchenne muscular dystrophy
Tracey, I., Dunn, J. F., & Radda, G. K. (1996) · Brain · doi:10.1093/brain/119.3.1039 · Cited by 51
Spatial learning and hippocampal long-term potentiation are not impaired in mdx mice
Sesay, A. K., Errington, M. L., Levita, L., & Bliss, T. V. P. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12747-6 · Cited by 49
DMD transcript imbalance determines dystrophin levels
Spitali, P., van den Bergen, J. C., Verhaart, I. E. C., Wokke, B., Janson, A. A. M., van den Eijnde, R., den Dunnen, J. T., Laros, J. F. J., Verschuuren, J. J. G. M., Hoen, P. A. C. '., et al. (2013) · The FASEB Journal · doi:10.1096/fj.13-232025 · Cited by 49
A scalable, clinically severe pig model for Duchenne muscular dystrophy
Stirm, M., Fonteyne, L. M., Shashikadze, B., Lindner, M., Chirivi, M., Lange, A., Kaufhold, C., Mayer, C., Medugorac, I., Kessler, B., et al. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049285 · Cited by 48
Matthews, D. J., James, K. A., Miller, L. A., Pandya, S., Campbell, K. A., Ciafaloni, E., Mathews, K. D., Miller, T. M., Cunniff, C., Meaney, F. J., et al. (2010) · Journal of Child Neurology · doi:10.1177/0883073810362762 · Cited by 47
Reinstadler, S. J., Fuernau, G., Eitel, C., de Waha, S., Desch, S., Metzler, B., Schuler, G., Thiele, H., & Eitel, I. (2016) · Circulation Journal · doi:10.1253/circj.cj-15-1135 · Cited by 47
Muntoni, F., Signorovitch, J., Sajeev, G., Lane, H., Jenkins, M., Dieye, I., Ward, S. J., McDonald, C., Goemans, N., Niks, E. H., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000201626 · Cited by 45
Long-term efficacy of AAV9-U7snRNA-mediated exon 51 skipping in mdx52 mice
Aupy, P., Zarrouki, F., Sandro, Q., Gastaldi, C., Buclez, P.-O., Mamchaoui, K., Garcia, L., Vaillend, C., & Goyenvalle, A. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.025 · Cited by 43
Miranda, R., Nagapin, F., Bozon, B., Laroche, S., Aubin, T., & Vaillend, C. (2015) · Molecular Autism · doi:10.1186/s13229-015-0053-9 · Cited by 42
Social stress is lethal in the mdx model of Duchenne muscular dystrophy
Razzoli, M., Lindsay, A., Law, M. L., Chamberlain, C. M., Southern, W. M., Berg, M., Osborn, J., Engeland, W. C., Metzger, J. M., Ervasti, J. M., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102700 · Cited by 42
Manning, J., Kulbida, R., Rai, P., Jensen, L. G., Bouma, J. E., Singh, S. P., O’Malley, D., & Yilmazer‐Hanke, D. (2014) · Experimental Physiology · doi:10.1113/expphysiol.2014.079475 · Cited by 41
van der Meulen, M., Amaya, J. M., Dekkers, O. M., & Meijer, O. C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062446 · Cited by 41
Dallérac, G., Perronnet, C., Chagneau, C., Leblanc-Veyrac, P., Samson-Desvignes, N., Peltekian, E., Danos, O., Garcia, L., Laroche, S., Billard, J.-M., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.05.012 · Cited by 41
Quantitative magnetic resonance imaging of the mdx mouse model of Duchenne muscular dystrophy
Dunn, J. F., & Zaim-Wadghiri, Y. (1999) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199910)22:10<1367::aid-mus5>3.0.co;2-h · Cited by 41
Dystrophins in developing retina: Dp260 expression correlates with synaptic maturation
Rodius, F., Claudepierre, T., Rosas‐Vargas, H., Cisneros, B., Montáñez, C., Dreyfus, H., Mornet, D., & Rendón, Á. (1997) · Neuroreport · doi:10.1097/00001756-199707070-00056 · Cited by 41
Functional involvement of cerebral cortex in duchenne muscular dystrophy
Lazzaro, V. D., Restuccia, D., Servidei, S., Nardone, R., Oliviero, A., Profice, P., Mangiola, F., Tonali, P. A., & Rothwell, J. C. (1998) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199805)21:5<662::aid-mus18>3.0.co;2-x · Cited by 41
The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy
Bengtsson, N. E., Tasfaout, H., & Chamberlain, J. S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.065 · Cited by 40
Emotional behavior and brain anatomy of the mdx52 mouse model of Duchenne muscular dystrophy
Saoudi, A., Zarrouki, F., Sebrié, C., Izabelle, C., Goyenvalle, A., & Vaillend, C. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049028 · Cited by 40
Kreis, R., Wingeier, K., Vermathen, P., Giger, E., Joncourt, F., Zwygart, K., Kaufmann, F., Boesch, C., & Steinlin, M. (2011) · NMR in Biomedicine · doi:10.1002/nbm.1582 · Cited by 40
Cognitive impairment appears progressive in the mdx mouse
Bagdatlioglu, E., Porcari, P., Greally, E., Blamire, A. M., & Straub, V. W. (2020) · Neuromuscular Disorders · doi:10.1016/j.nmd.2020.02.018 · Cited by 39
Cognitive flexibility deficits in a mouse model for the absence of full-length dystrophin
Remmelink, E., Aartsma‐Rus, A., Smit, A. B., Verhage, M., Loos, M., & van Putten, M. (2016) · Genes, Brain and Behavior · doi:10.1111/gbb.12301 · Cited by 38
Descriptive phenotype of obsessive compulsive symptoms in males with Duchenne muscular dystrophy
Lee, A. J., Buckingham, E. T., Kauer, A. J., & Mathews, K. D. (2018) · Journal of Child Neurology · doi:10.1177/0883073818774439 · Cited by 38
The different impact of a high fat diet on dystrophic mdx and control C57Bl/10 mice.
Radley‐Crabb, H. G., Fiorotto, M. L., & Grounds, M. D. (2011) · PLoS Currents · doi:10.1371/currents.rrn1276 · Cited by 37
Lorusso, M. L., Civati, F., Molteni, M., Turconi, A. C., Bresolin, N., & D’Angelo, M. G. (2012) · Child Neuropsychology · doi:10.1080/09297049.2012.660912 · Cited by 37
Characterization of brain dystrophins absence and impact in dystrophin-deficient Dmdmdx rat model
Caudal, D., François, V., Lafoux, A., Ledevin, M., Anegon, I., Le Guiner, C., Larcher, T., & Huchet, C. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230083 · Cited by 35
Comparing mouse and human brains
Wong, H. H.-W., Chou, C. Y. C., Watt, A. J., & Sjöström, P. J. (2023) · eLife · doi:10.7554/elife.90017 · Cited by 34
Chaussenot, R., Amar, M., Fossier, P., & Vaillend, C. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1259-6 · Cited by 34
Saoudi, A., Barberat, S., Coz, O. L., Vacca, O., Doisy, M., Tensorer, T., Śliwiński, É., García, L., Muntoni, F., Vaillend, C., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.009 · Cited by 33
Lv, S.-Y., Zou, Q.-H., Cui, J.-L., Zhao, N., Hu, J., Long, X.-Y., Sun, Y.-C., He, J., Zhu, C.-Z., He, Y., et al. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2718 · Cited by 33
Detailed genetic and functional analysis of the hDMDdel52/ mdx mouse model
Yavas, A., Weij, R., van Putten, M., Kourkouta, E., Beekman, C., Puoliväli, J., Bragge, T., Ahtoniemi, T., Knijnenburg, J., Hoogenboom, M. E., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0244215 · Cited by 33
The role of dystrophin isoforms and interactors in the brain
Tetorou, K., Aghaeipour, A., Singh, S., Morgan, J. E., & Muntoni, F. (2024) · Brain · doi:10.1093/brain/awae384 · Cited by 32
Abnormalities in brain biochemistry associated with lack of dystrophin: studies of the mdx mouse
Rae, C., Griffin, J. L., Blair, D. H., Bothwell, J. H., Bubb, W. A., Maitland, A., & Head, S. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(01)00253-x · Cited by 32
Etiology of intellectual impairment in Duchenne muscular dystrophy
Al-Qudah, A. A., Kobayashi, J., Chuang, S., Dennis, M., & Ray, P. (1990) · Pediatric Neurology · doi:10.1016/0887-8994(90)90081-b · Cited by 32
Zarrouki, F., Relizani, K., Bizot, F., Tensorer, T., García, L., Vaillend, C., & Goyenvalle, A. (2022) · Annals of Neurology · doi:10.1002/ana.26409 · Cited by 31
Helleringer, R., Le Verger, D., Li, X., Izabelle, C., Chaussenot, R., Belmaati-Cherkaoui, M., Dammak, R., Decottignies, P., Daniel, H., Galante, M., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033258 · Cited by 31
Astrea, G., Pecini, C., Gasperini, F., Brisca, G., Scutifero, M., Bruno, C., Santorelli, F. M., Cioni, G., Politano, L., Chilosi, A. M., et al. (2015) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2015.07.025 · Cited by 31
Longitudinal follow-up of verbal span and processing speed in Duchenne muscular dystrophy
Hellebrekers, D. M. J., Doorenweerd, N., Sweere, D. J. J., van Kuijk, S. M. J., Aartsma-Rus, A. M., Klinkenberg, S., Vles, J. S. H., & Hendriksen, J. G. M. (2020) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2020.01.002 · Cited by 31
Schwartz, C. E., Stark, R. B., Audhya, I. F., & Gooch, K. L. (2021) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-021-00386-y · Cited by 30
Snow, W. M., Anderson, J. E., & Fry, M. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.10.017 · Cited by 28
Gai, B. M., Bortolatto, C. F., Heck, S. O., Stein, A. L. A., Duarte, M. M. M. F., Zeni, G. R., & Nogueira, C. W. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3361-9 · Cited by 28
Lack of dystrophin results in abnormal cerebral diffusion and perfusion in vivo
Goodnough, C. L., Gao, Y., Li, X., Qutaish, M. Q., Goodnough, L. H., Molter, J., Wilson, D., Flask, C. A., & Yu, X. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.08.053 · Cited by 28
Zarrouki, F., Goutal, S., Vacca, O., García, L., Tournier, N., Goyenvalle, A., & Vaillend, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012617 · Cited by 28
Stroke in Duchenne muscular dystrophy: a retrospective longitudinal study in 54 patients
Winterholler, M., Holländer, C., Kerling, F., Weber, I., Dittrich, S., Türk, M., & Schröder, R. (2016) · Stroke · doi:10.1161/strokeaha.116.013678 · Cited by 28
Vaillend, C., & Chaussenot, R. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx013 · Cited by 27
Pascual-Morena, C., Cavero-Redondo, I., Martínez-Vizcaíno, V., Sequí-Domínguez, I., Fernández-Bravo-Rodrigo, J., & Jiménez-López, E. (2023) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-221586 · Cited by 27
Neurocognitive impairment in mdx mice
Comim, C. M., Ventura, L., Freiberger, V., Dias, P., Bragagnolo, D., Dutra, M. L., Amaral, R. A., Camargo-Fagundes, A. L. S., Reis, P. A., Castro-Faria-Neto, H. C., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1573-7 · Cited by 27
Preethish-Kumar, V., Shah, A., Kumar, M., Ingalhalikar, M., Polavarapu, K., Afsar, M., Rajeswaran, J., Vengalil, S., Nashi, S., Thomas, P. T., et al. (2020) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6604 · Cited by 24
Mortazavi, M., Ren, Y., Saini, S., Antaki, D., St. Pierre, C. L., Williams, A., Sohni, A., Wilkinson, M. F., Gymrek, M., Sebat, J., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100102 · Cited by 24
Xu, S., Shi, D., Pratt, S. J. P., Zhu, W., Marshall, A., & Lovering, R. M. (2015) · Neuromuscular Disorders · doi:10.1016/j.nmd.2015.07.003 · Cited by 24
Wechsler Scale Intelligence Testing in Males with Dystrophinopathies: A Review and Meta-Analysis
Weerkamp, P. M. M., Mol, E. M., Sweere, D. J. J., Schrans, D. G. M., Vermeulen, R. J., Klinkenberg, S., Hurks, P. P. M., & Hendriksen, J. G. M. (2022) · Brain Sciences · doi:10.3390/brainsci12111544 · Cited by 23
Doorenweerd, N., de Rover, M., Marini-Bettolo, C., Hollingsworth, K. G., Niks, E. H., Hendriksen, J. G. M., Kan, H. E., & Straub, V. (2021) · Brain Imaging and Behavior · doi:10.1007/s11682-020-00422-3 · Cited by 23
Yamamoto, K., Yamada, D., Kabuta, T., Takahashi, A., Wada, K., & Sekiguchi, M. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.05.006 · Cited by 23
Barboni, M. T. S., Vaillend, C., Joachimsthaler, A., Liber, A. M. P., Khabou, H., Roux, M. J., Vacca, O., Vignaud, L., Dalkara, D., Guillonneau, X., et al. (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.2.11 · Cited by 20
Lionarons, J. M., Hellebrekers, D. M. J., Klinkenberg, S., Faber, C. G., Vles, J. S. H., & Hendriksen, J. G. M. (2019) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2018.09.005 · Cited by 20
Alexander, M. S., Gasperini, M. J., Tsai, P. T., Gibbs, D. E., Spinazzola, J. M., Marshall, J. L., Feyder, M. J., Pletcher, M. T., Chekler, E. L. P., Morris, C. A., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.174 · Cited by 19
Hendriksen, J. G. M., Klinkenberg, S., Collin, P., Wong, B., Niks, E. H., & Vles, J. S. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.08.003 · Cited by 19
Saoudi, A., Fergus, C., Gileadi, T. E., Montanaro, F., Morgan, J. E., Kelly, V. P., Tensorer, T., García, L., Vaillend, C., Muntoni, F., et al. (2023) · Cells · doi:10.3390/cells12060908 · Cited by 19
Preethish-Kumar, V., Shah, A., Polavarapu, K., Kumar, M., Safai, A., Vengalil, S., Nashi, S., Deepha, S., Govindaraj, P., Afsar, M., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-021-10789-y · Cited by 19
Catapano, F., Alkharji, R., Chambers, D., Singh, S., Aghaeipour, A., Malhotra, J., Ferretti, P., Phadke, R., & Muntoni, F. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-01996-z · Cited by 19
Hoogland, G., Hendriksen, R. G. F., Slegers, R. J., Hendriks, M. P. H., Schijns, O. E. M. G., Aalbers, M. W., & Vles, J. S. H. (2019) · Hippocampus · doi:10.1002/hipo.23015 · Cited by 19
Enhanced homosynaptic LTD in cerebellar Purkinje cells of the dystrophic MDX mouse
Anderson, J. L., Morley, J. W., & Head, S. I. (2010) · Muscle & Nerve · doi:10.1002/mus.21467 · Cited by 17
Biagi, L., Lenzi, S., Cipriano, E., Fiori, S., Bosco, P., Cristofani, P., Astrea, G., Pini, A., Cioni, G., Mercuri, E., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0250420 · Cited by 17
Validation of DE50-MD dogs as a model for the brain phenotype of Duchenne muscular dystrophy
Crawford, A. H., Hildyard, J. C. W., Rushing, S. A. M., Wells, D. J., Diez-Leon, M., & Piercy, R. J. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049291 · Cited by 17
Sensorineural Hearing Loss in the mdx Mouse: A Model of Duchenne Muscular Dystrophy
Raynor, E. M., & Mulroy, M. J. (1997) · The Laryngoscope · doi:10.1097/00005537-199708000-00009 · Cited by 17
Verhaeg, M., Adamzek, K., van de Vijver, D., Putker, K., Engelbeen, S., Wijnbergen, D., Overzier, M., Suidgeest, E., van der Weerd, L., Aartsma‐Rus, A., et al. (2024) · Genes, Brain and Behavior · doi:10.1111/gbb.12895 · Cited by 16
Self-citationExecutive skills and academic achievement in the dystrophinopathies
Fee, R. J., Montes, J., Stewart, J. L., & Hinton, V. J. (2018) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617717001333 · Cited by 15
Engelbeen, S., Aartsma-Rus, A., Koopmans, B., Loos, M., & van Putten, M. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.629043 · Cited by 15
Genetic background determines behavioral responses during fear conditioning
Seemiller, L. R., Mooney-Leber, S. M., Henry, E., McGarvey, A., Druffner, A., Peltz, G., & Gould, T. J. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107501 · Cited by 14
Impact of distinct dystrophin gene mutations on behavioral phenotypes of Duchenne muscular dystrophy
Saoudi, A., Mitsogiannis, M. D., Zarrouki, F., Fergus, C., Stojek, E., Talavera, S., Moore-Frederick, D., Kelly, V. P., Goyenvalle, A., Montanaro, F., et al. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050707 · Cited by 14
Longitudinal evaluation of working memory in duchenne muscular dystrophy
Thangarajh, M., Elfring, G. L., & Trifillis, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092940 · Cited by 14
Lewon, M., Peters, C. M., Van Ry, P. M., Burkin, D. J., Hunter, K. W., & Hayes, L. J. (2017) · Behavioural Processes · doi:10.1016/j.beproc.2017.05.012 · Cited by 14
Kreko-Pierce, T., & Pugh, J. R. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.926518 · Cited by 14
Temporalis muscle hypertrophy and reduced skull eccentricity in Duchenne muscular dystrophy
Straathof, C. S. M., Doorenweerd, N., Wokke, B. H. A., Dumas, E. M., van den Bergen, J. C., van Buchem, M. A., Hendriksen, J. G. M., Verschuuren, J. J. G. M., & Kan, H. E. (2014) · Journal of Child Neurology · doi:10.1177/0883073813518106 · Cited by 13
Networking to optimize Dmd exon 53 skipping in the brain of mdx52 mouse model
Doisy, M., Vacca, O., Fergus, C., Gileadi, T., Verhaeg, M., Saoudi, A., Tensorer, T., Garcia, L., Kelly, V. P., Montanaro, F., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11123243 · Cited by 13
Self-citationPaúl-González, S., Aragón, J., Martinez, G. R., Romo‐Yáñez, J., & Montáñez, C. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.03.142 · Cited by 13
Flynn, J. M., Brown, E. J., & Clark, A. G. (2021) · G3 Genes|Genomes|Genetics · doi:10.1093/g3journal/jkab184 · Cited by 12
Schwartz, C. E., Biletch, E., Stuart, R. B. B., & Rapkin, B. D. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00500-8 · Cited by 11
Geuens, S., Van Dessel, J., Govaarts, R., Ikelaar, N. A., Meijer, O. C., Kan, H. E., Niks, E. H., Goemans, N., Lemiere, J., Doorenweerd, N., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51922 · Cited by 11
Self-citationAltered visual processing in the mdx52 mouse model of Duchenne muscular dystrophy
Barboni, M. T. S., Liber, A. M. P., Joachimsthaler, A., Saoudi, A., Goyenvalle, A., Rendon, A., Roger, J. E., Ventura, D. F., Kremers, J., & Vaillend, C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105288 · Cited by 11
Gene therapy approval for Duchenne muscular dystrophy: a European perspective
Jolly, H., Aartsma-Rus, A., Bertini, E., De Waele, L., Haberlova, J., Klein, A., Niks, E., & Servais, L. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00717-2 · Cited by 11
Genetically dystrophic mdx/mdx mice exhibit decreased response to nicotine in passive avoidance
Coccurello, R., Castellano, C., Paggi, P., Mele, A., & Oliverio, A. (2002) · Neuroreport · doi:10.1097/00001756-200207020-00030 · Cited by 11
Increased Vulnerability of Auditory System to Noise Exposure in mdx Mice
Chen, T., Chen, S., Wang, D., & Hsieh, Y. (2002) · The Laryngoscope · doi:10.1097/00005537-200203000-00021 · Cited by 11
Visual discrimination, serial reversal, and extinction learning in the mdx mouse
Dickson, P. E., & Mittleman, G. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00200 · Cited by 9
The behavioural consequences of dystrophinopathy
Verhaeg, M. A. T., van der Pijl, E. M., van de Vijver, D., Winter, C. L. T.-D., Stan, T. L., van Uffelen, A., Censoni, L., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052047 · Cited by 9
Self-citationDoorenweerd, N., Hooijmans, M. T., Schubert, S. A., WEBB, A. G., Straathof, C. S. M., van Zwet, E. W., van Buchem, M. A., Verschuuren, J. J. G. M., Hendriksen, J. G. M., Niks, E. H., et al. (2017) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-160201 · Cited by 9
Gene editing for duchenne muscular dystrophy: from experimental models to emerging therapies
Haque, U. S., & Yokota, T. (2025) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s495536 · Cited by 8
Reduction of acethylcolinesterase activity in the brain of mdx mice
Comim, C. M., Moraz, T., Abreu, I., Fraga, D. B., Ghedim, F. V., Mildner, N., Tuon, L., Vainzof, M., Zugno, A. I., & Quevedo, J. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.02.017 · Cited by 8
Bello, L., Riguzzi, P., Albamonte, E., Astrea, G., Battini, R., Barp, A., Berardinelli, A. L., Bertini, E. S., Brolatti, N., Bruno, C., et al. (2025) · Drugs in R&D · doi:10.1007/s40268-025-00512-x · Cited by 8
Xu, S., Tang, S., Li, X., Iyer, S. R., & Lovering, R. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00739 · Cited by 7
Crawford, A. H., Hornby, N. L., de la Fuente, A. G., & Piercy, R. J. (2023) · BMC Neuroscience · doi:10.1186/s12868-023-00788-2 · Cited by 7
Longitudinal motor function in proximal versus distal DMD pathogenic variants
Thangarajh, M., Bello, L., Gordish‐Dressman, H., & CINRG‐DNHS Investigators (2021) · Muscle & Nerve · doi:10.1002/mus.27371 · Cited by 7
Noda, S., Murakami, A., Kimura, S., Minamiyama, M., Katsuno, M., & Kuru, S. (2021) · Internal Medicine · doi:10.2169/internalmedicine.7248-21 · Cited by 6
Govaarts, R., Doorenweerd, N., Najac, C., Broek, E. M., Tamsma, M., Hollingsworth, K. G., Niks, E. H., Ronen, I., Straub, V. W., & Kan, H. E. (2024) · NMR in Biomedicine · doi:10.1002/nbm.5212 · Cited by 5
Self-citation
Cited by
Vacca, O., Doisy, M., Nagy, C., Saoudi, A., Phongsavanh, X., Coz, O. L., Vaillend, C., & Goyenvalle, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.09.757591 · Cited by 1
The Multi-System Roles of Dp71 Dystrophin Isoforms in Duchenne Muscular Dystrophy
Wilton-Clark, H., Raza, A., & Yokota, T. (2026) · Muscles · doi:10.3390/muscles5020043
Proteomics of Duchenne muscular dystrophy
Dowling, P., Swandulla, D., & Ohlendieck, K. (2026) · Advances in clinical chemistry · doi:10.1016/bs.acc.2026.10.003
Egiian, M., Eskandari, R., Tyler, S., Diop, M., & Hoffman, L. (2026) · Neuromuscular Disorders · doi:10.1016/j.nmd.2026.107463
Cao, Z., Yin, L., Zhang, X., Hong, E., Du, J., Liang, R., Tang, Y., & Zhang, G. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04863-y
Metadata
- Authors
- Verhaeg, M. A. T., Govaarts, R., & van Putten, M.
- Affiliations
- Leiden University Medical Center (NL)
- Corresponding author
- Govaarts, Rosanne
- van Putten, Maaike
- Venue
- Disease Models & Mechanisms
- Publisher
- The Company of Biologists
- Published
- 2025-07-01
- Volume
- 18
- Issue
- 7
- ISSN
- 1754-8403 (ISSN-L)
- 1754-8411
- PMC
- PMC12352290
- OpenAlex
- W4412820802
- Cited by
- 5
- References
- 204
- Citations by year
- 2026: 5
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Disease Models & Mechanisms (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Horizon 2020 Framework Programme (847826)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- Duchenne muscular dystrophy, neuropathology, dystrophin, DMD gene mutations, cognitive impairment, autism spectrum disorder, obsessive-compulsive disorder, attention deficit hyperactivity disorder, anxiety, social dysfunction, learning disabilities, exon skipping, dystrophin isoforms, brain development, behavioural deficits
- MeSH terms
- Animals, Brain, Disease Models, Animal, Humans, Dystrophin, Muscular Dystrophy, Duchenne, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.